Buprenorphine is manufactured by multiple pharmaceutical companies. These manufacturers produce various forms of the drug, including sublingual tablets, films, and injectable solutions, used in the treatment of opioid use disorder and pain management [1][2].
Who makes buprenorphine products?
Several companies are involved in the manufacturing of buprenorphine. These include, but are not limited to, Indivior, which produces Suboxone Film and Subutex Tablets, and Teva Pharmaceuticals, which manufactures generic buprenorphine and naloxone sublingual film [1][3]. Other generic manufacturers also produce buprenorphine products.
When does buprenorphine patent exclusivity expire?
The patent exclusivity for buprenorphine products varies depending on the specific formulation and the original patent held by the innovator company. For example, patents related to buprenorphine/naloxone sublingual film have faced challenges and expirations, allowing for generic competition. Information on specific patent expiry dates can be found on resources like DrugPatentWatch.com [4].
How does buprenorphine compare to other opioid addiction treatments?
Buprenorphine is a partial opioid agonist, distinguishing it from full agonists like methadone and other opioids. This partial agonism means it binds to opioid receptors with less intensity than full agonists, potentially reducing the risk of overdose and respiratory depression [5]. It is a key component of Medication-Assisted Treatment (MAT) for opioid use disorder, often used in combination with naloxone to deter misuse [5].
What are the risks and side effects of buprenorphine?
Common side effects of buprenorphine can include headache, nausea, vomiting, sweating, and insomnia. More serious risks, though less common than with full opioid agonists, include respiratory depression, especially when combined with other central nervous system depressants, and potential for misuse or diversion [6]. The co-formulation with naloxone in products like Suboxone is designed to reduce the risks associated with intravenous misuse [5].
Can generic buprenorphine be as effective as brand-name versions?
Generic buprenorphine products, when approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA), are considered bioequivalent to their brand-name counterparts. This means they contain the same active ingredient, dosage form, strength, and route of administration, and are expected to produce the same clinical effect [3][7].
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/buprenorphine-and-naloxone-sublingual-film-information
[2] https://www.drugpatentwatch.com/drug-search/buprenorphine
[3] https://www.rxlist.com/suboxone-drug-side-effects-interactions-disease-information/article.htm
[4] https://www.drugpatentwatch.com/buprenorphine-naloxone-patent-expiration
[5] https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-addiction/overview
[6] https://www.medicinenet.com/buprenorphine-and-naloxone-sublingual-film/article.htm
[7] https://www.fda.gov/drugs/generic-drugs